Skip to main content
. Author manuscript; available in PMC: 2022 May 12.
Published in final edited form as: Nat Aging. 2021 Dec 6;1(12):1175–1188. doi: 10.1038/s43587-021-00138-z

Extended Data Fig 7. Longitudinal analyses reveal that sildenafil usage is significantly associated with reduced likelihood of AD in individuals with type-2 diabetes (T2D).

Extended Data Fig 7.

Five comparator analyses were conducted including: (a) sildenafil vs. matched non- sildenafil, (b) sildenafil vs. diltiazem (an anti-hypertensive drug), (c) sildenafil vs. losartan (an anti-hypertensive drug candidate in an AD clinical trial [ClinicalTrials.gov Identifier: NCT02913664]), (d) sildenafil vs. glimepiride (an anti-diabetic drug), and (e) sildenafil vs. metformin (an anti-diabetic drug in an AD clinical trial [ClinicalTrials.gov Identifier: NCT00620191]). For each comparator, we estimated the propensity score by using the variables described in Table 1. Then, we estimated the un-stratified Kaplan-Meier curves, conducted propensity score stratified (n strata = 10) log-rank test and Cox model.